“Big World. Molecular Medicine. One Community” – Cancer Genetics’ Contributions to AMP this Year

Written by: Anna Israyelyan, MD, PhD
Manager, Biopharma Solutions

Published on:
November 8th, 2016

Anna Israyelyan, MD, PhD
Dr. Israyelyan joined CGI in 2015. She has over 15 years of extensive cancer research and management experience in industry and academia covering wide range of medical areas, including basic, translational, and clinical research. Anna is an active member of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and American Association for the Advancement of Science (AAAS). Dr. Israyelyan has a scientific advisory role with matrix management of scientific, technical, and operational aspects related to various biopharma projects and collaborations involving biomarkers in solid tumors and hematologic malignancies.

Every year, the Association for Molecular Pathology (AMP) hosts a 3-day event, which provides high quality content  for the global molecular pathology community. As a leader in enabling precision medicine for oncology through molecular markers and diagnostics,  Cancer Genetics, Inc. (CGI) will contribute to the meeting’s theme through its carefully selected presentations and important insights. With a global footprint and strong collaborations, CGI delivers highest quality molecular diagnostics to improve patient care and has a unique role in the big world of molecular medicine.

One Cancer Type with Incidence Rates Still on the Rise… and in Desperate Need of a Comprehensive Genomic Profiling Tool

While many cancer incidence rates have declined over time, renal cancer incidence rates continue to rise. In collaboration with prominent cancer centers and academic institutions, including Memorial Sloan Kettering Cancer Center (MSKCC), Cleveland Clinic, Huntsman Cancer Center at University of Utah, and University Hospital of Paris, CGI has developed and rigorously validated a next generation sequencing (NGS) panel for renal cancer, Focus:: Renal, which has the ability to provide comprehensive genomic profiling aiding in implementation and development of personalized therapies for renal cancer patients.

Focus:: Renal is CLIA-validated and commercially-launched, and is the only panel of its kind able to simultaneously assess genome-wide copy number changes and SNP genoptypes along with renal cancer-related mutations. It provides comprehensive coverage of renal cancer-related markers and pathways, and has a sample-agnostic workflow, covering various sample types, including those with minimal starting material (e.g. FFPE).

To learn more about the unique panel Focus::Renaland to chat with the people directly involved in the development and validation of this extremely important genomic profiling tool, please meet Dr. Banumathy Gowrishankar, Principal Scientist, who will be presenting a poster on Focus::Renal on Saturday, November 12, 9:45am – 10:45am.

Abstract Title:  Analytical Validation of a Targeted Next-Generation Sequencing Assay (Mutation, Copy Number, and SNPs) for Prognostic Utility in Patients with Clear Cell Renal Cell Carcinoma

Poster Session:  Saturday, November 12, 9:45am – 10:45am
Poster Number:  S113
Category:  Solid Tumors


The Most Clinically Actionable NGS Panel in Precision Medicine

focus-lymphoma-imageAnother “Big World” proprietary panel by CGI, the Focus::Lymphoma panel, provides a powerful, clinically validated tool for molecular characterization of lymphomas, B-cell neoplasms, in particular. It is the most comprehensive and clinically actionable NGS panel in precision medicine, available for use in a clinical setting, and currently being used to power several clinical trials with top biotech and pharmaceutical companies. The panel covers the most common types of B-cell lymphomas, which represent nearly 300,000 patients living with the disease in the U.S.A.

To learn more about the panel architecture, its ability to provide critical genomic information to improve patient management and guide therapy decisions, and customized reporting options, please meet Dr. Charles Ma, Associate Director, who is going to present important details about the Focus::Lymphoma panel on Saturday, November 12, 9:45am -10:45am.

Abstract Title:  A 220-Gene Targeted Next-Generation Sequencing Panel for the Detection of Somatic Variants in Mature B-Cell Neoplasms

Poster Session:  Saturday, November 12, 9:45am – 10:45am
Poster Number:  H71
Category:  Hematopathology

Another Big World Problem on Its Way to Being Solved

While premalignant lesions are commonly diagnosed, little is known about genomic features influencing risk of progression to carcinoma: another “Big World” problem, which if solved, may provide a basis for cancer prevention. CGI Medical Director Dr. Daniel Duncan’s work on premalignant mucosal lesions explored whether molecular analyses of premalignant lesions utilizing an NGS panel may be able to predict progression to carcinoma. Dr. Duncan’s findings reveal NGS can be utilized to sequence small lesions. He determines actionable variants can be detectable in nearly a third of gastric adenocarcinomas, which improves options for targeted therapy, refines prognosis, and helps select clinical trials for patients. His work justifies further larger studies to stratify lesions for risk of progression to cancer.

To find out more about this exciting pilot study and to connect with Dr. Duncan, you can meet him on Friday, November 11, 2:30pm – 3:30pm.

Abstract Title:  Carcinoma-Related Mutation Detected in 23% of Macrodissected Premalignant Gastric Mucosal Lesions

Poster Session:  Friday, November 11, 2:30pm – 3:30pm
Poster Number:  S70
Category:  Solid Tumors

Please reach out to me to schedule individual meetings with any of our investigators:

Anna Israyelyan, MD, PhD
Clinical Affairs Manager – Cancer Genetics, Inc.
Tel: 323.224.3900 x175

You can also connect with me on LinkedIn